Side-by-side comparison of AI visibility scores, market position, and capabilities
SF dementia care coordination platform with Johns Hopkins MIND at Home partnership; YC $6.5M with $1.9M revenue connecting patients and caregivers through virtual care navigation for Alzheimer's management.
Craniometrix is a San Francisco-based digital health company providing virtual dementia care coordination — connecting dementia patients, family caregivers, and healthcare providers through a telemedicine platform that delivers cognitive assessment, care planning, caregiver education, and ongoing care management for Alzheimer's and related dementia conditions. Founded by CEO Nikhil Patel and backed by Y Combinator with $6-6.5 million raised from Y Combinator, Quiet Capital, and Defy.vc, Craniometrix generated $1.9 million in revenue in 2024 and partners with the Johns Hopkins MIND at Home program — a validated community-based dementia care model developed by Johns Hopkins University School of Medicine.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.